These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21572121)

  • 1. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.
    Holland-Fischer P; Grønbæk H; Sandahl TD; Moestrup SK; Riggio O; Ridola L; Aagaard NK; Møller HJ; Vilstrup H
    Gut; 2011 Oct; 60(10):1389-93. PubMed ID: 21572121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis.
    Grønbaek H; Sandahl TD; Mortensen C; Vilstrup H; Møller HJ; Møller S
    Aliment Pharmacol Ther; 2012 Jul; 36(2):173-80. PubMed ID: 22591184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kupffer cell activation and portal hypertension.
    Steib CJ
    Gut; 2011 Oct; 60(10):1307-8. PubMed ID: 21708827
    [No Abstract]   [Full Text] [Related]  

  • 4. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
    Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
    Mortensen C; Karlsen S; Grønbæk H; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F
    Liver Int; 2013 Oct; 33(9):1309-15. PubMed ID: 23763259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
    Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL
    Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites.
    Alam I; Bass NM; Bacchetti P; Gee L; Rockey DC
    Am J Gastroenterol; 2000 Jan; 95(1):199-203. PubMed ID: 10638583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension.
    Luca A; Miraglia R; Caruso S; Milazzo M; Gidelli B; Bosch J
    Liver Transpl; 2006 Aug; 12(8):1237-43. PubMed ID: 16741929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis.
    Waidmann O; Brunner F; Herrmann E; Zeuzem S; Piiper A; Kronenberger B
    J Hepatol; 2013 May; 58(5):956-61. PubMed ID: 23333526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
    La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
    Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Portal levels of the isoprostane F2 alpha-III, a marker of lipid peroxidation, do not correlate with increased portal pressure in cirrhotic patients.
    Praticò D; Rossi E; Merli M; Riggio O; FitzGerald GA; Violi F
    J Investig Med; 1998 Dec; 46(9):430-4. PubMed ID: 9861778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.
    Geilswijk M; Thomsen KL; Pedersen EB; Vilstrup H; Grønbæk H
    Scand J Gastroenterol; 2015 Apr; 50(4):454-61. PubMed ID: 25637473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic arterial buffer response in patients with advanced cirrhosis.
    Gülberg V; Haag K; Rössle M; Gerbes AL
    Hepatology; 2002 Mar; 35(3):630-4. PubMed ID: 11870377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery.
    Kim JJ; Dasika NL; Yu E; Fontana RJ
    J Clin Gastroenterol; 2009 Jul; 43(6):574-9. PubMed ID: 19169145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transjugular intrahepatic portosystemic shunt and combination with percutaneous transhepatic or transsplenic approach for the treatment of portal vein thrombosis with or without cavernomatous transformation].
    Han GH; Meng XJ; Yin ZX; Wang JH; He CY; Liang J; Guo XG; Liu J; Ding L; Wu KC; Fan DM
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1549-52. PubMed ID: 19953883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of percutaneous intrahepatic portosystemic shunt on splanchnic and systemic hemodynamics in patients with portal hypertension].
    François E; García-Pagán JC; Bru C; Feu F; Gilabert R; Escorsell A; Bosch J; Rodés J
    Gastroenterol Hepatol; 1997 Jan; 20(1):1-4. PubMed ID: 9072189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis.
    Biecker E; Roth F; Heller J; Schild HH; Sauerbruch T; Schepke M
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):846-52. PubMed ID: 17873607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.
    Lotterer E; Wengert A; Fleig WE
    Hepatology; 1999 Mar; 29(3):632-9. PubMed ID: 10051460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.